BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Posted by George Bondi on Nov 9th, 2026

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have earned an average rating of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $20.38.

A number of brokerages have recently commented on BCRX. JPMorgan Chase & Co. lifted their price target on BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Wednesday, September 30th. Weiss Ratings downgraded BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 8th. Wedbush dropped their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday.

View Our Latest Stock Report on BioCryst Pharmaceuticals

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several large investors have recently modified their holdings of BCRX. BlackRock Inc. acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter worth approximately $238,930,000. Jupiter Topco LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at $95,268,000. Janus Henderson Group PLC increased its position in shares of BioCryst Pharmaceuticals by 20.3% during the first quarter. Janus Henderson Group PLC now owns 8,908,506 shares of the biotechnology company’s stock worth $84,854,000 after buying an additional 1,504,120 shares during the period. Perceptive Advisors LLC increased its position in shares of BioCryst Pharmaceuticals by 135.1% during the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock worth $70,772,000 after buying an additional 4,271,504 shares during the period. Finally, Aberdeen Group plc increased its position in shares of BioCryst Pharmaceuticals by 21.8% during the third quarter. Aberdeen Group plc now owns 6,468,726 shares of the biotechnology company’s stock worth $53,884,000 after buying an additional 1,157,855 shares during the period. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX opened at $7.69 on Wednesday. BioCryst Pharmaceuticals has a twelve month low of $6.23 and a twelve month high of $11.22. The company has a market cap of $1.98 billion, a price-to-earnings ratio of -5.42 and a beta of 0.55. The business’s fifty day moving average is $8.46 and its 200 day moving average is $8.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The business had revenue of $180.29 million during the quarter, compared to analysts’ expectations of $165.67 million. BioCryst Pharmaceuticals had a negative return on equity of 92.91% and a negative net margin of 37.40%. The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.06 EPS. On average, research analysts anticipate that BioCryst Pharmaceuticals will post -2.26 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

(Get Free Report)

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.